What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
17 juil. 2024 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk...
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
11 juil. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL)...
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
09 juil. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
Myriad Genetics Earns 2024 Great Place To Work® Certification™
02 juil. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work...
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
24 juin 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health...
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
11 juin 2024 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at...
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
04 juin 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel...
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
03 juin 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official...
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
30 mai 2024 17h55 HE
|
Myriad Genetics, Inc.
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved...
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
23 mai 2024 18h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies...